Background Although 90% of infections with the novel coronavirus 2 (COVID-19) are mild,
many patients progress to acute respiratory distress syndrome (ARDS) which carries a high …

As the number of confirmed cases and resulting death toll of the COVID‐19 pandemic
continue to increase around the globe‐especially with the emergence of new mutations of …

Immunomodulatory therapeutic approaches such as glucocorticoid therapy, convalescent
plasma therapy, and antiinterleukin (IL-6) receptor antibody therapy have been used for the …

Background and Objectives The novel coronavirus disease 2019 (COVID-19) has been a
pandemic health issue in 30 January 2020. The mortality rate is as high as 50% in critically …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-caused coronavirus
disease 2019 (COVID-19) pandemic has become a global health crisis with an extremely …

Severe cases of COVID-19 infection, often leading to death, have been associated with
variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal …

The mortality rate of critically ill patients with acute respiratory distress syndrome (ARDS) is
30.9% to 46.1%. The emergence of the coronavirus disease 2019 (Covid-19) has become a …

A worldwide pandemic known as coronavirus disease-19 (COVID-19) has caused various
clinical complications, ranging from carriers without symptoms to acute respiratory distress …

Background Treatment of acute respiratory distress syndrome (ARDS) associated with
COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive …

Background and aims The main causes of death in patients with severe Coronavirus
disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan …